-
FDA approves first implantable drug to treat opioid addiction
The Washington Post (5/26, McGinley) reports in “To Your Health” that the Food and Drug Administration “on Thursday approved the first implantable drug to deliver long-lasting medication to people addicted to opioids.” The implant, known as Probuphine, “administers the anti-addiction drug buprenorphine in a continuous dose for six months.” It is “intended for people who are already stable on low doses of the drug.” The AP (5/26, Perrone) reports that the “first-of-a-kind device” could “help patients avoid relapses that can… Read More
-
CDC Health Advisory: Increases in Fentanyl Drug Confiscations
Increases in Fentanyl Drug Confiscations and Fentanyl-related Overdose Fatalities Summary The Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA) are investigating recent increases in fentanyl-related unintentional overdose fatalities in multiple… Read More
-
1st drug in the world manufactured by 3-D printing wins FDA approval
In a world first, the US Food and Drug Administration has given the go-ahead for a 3D-printed pill to be produced: a dissolvable tablet that treats seizures.” Aprecia Pharmaceuticals announced on Monday that the FDA… Read More
-
Hydrocodone Reclassification: What physicians need to know
Recently, the Drug Enforcement Administration (DEA) issued a final rule rescheduling hydrocodone combination products (HCPs) into Controlled Substance Schedule II, effective October 6, 2014. Rescheduling issues directly related to Arkansas: Under Arkansas law, physician… Read More
-
Hydrocodone Drugs Moving to Schedule II Oct 6
The U.S. Drug Enforcement Administration (DEA) published a final rule Aug. 22 that changes the controlled substance scheduling of hydrocodone combination products (HCP) from Schedule III to Schedule II. The change is scheduled to take effect… Read More
-
New restrictions on hydrocodone to take effect
Article below from USA Today Online. Read more at federalregister.gov. WASHINGTON (AP) — The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the… Read More
-
New Information On Acetaminophen
FDA Acetaminophen Limits in Combination Products Effective January 14, 2014, it will become unlawful to purchase or sell any narcotic/acetaminophen combination products that contain greater than 325mg of acetaminophen. This ban on high dosage acetaminophen… Read More
-
FDA Warns Oral Anti-Fungal May Cause Adrenal, Liver Problems
The Wall Street Journal (7/27, Burton, Subscription Publication, 2.29M) reported that the US Food and Drug Administration announced Friday that it was limiting the use of Johnson & Johnson’s oral, anti-fungal therapy, Nizoral (ketoconazole). Although… Read More
-
FDA Drug Alert Issued
An important FDA-approved Drug Alert for INVIRASE affecting Cardiology, Infectious Disease, Internal Medicine, Pediatrics, Nurse Practitioners, and Pharmacies was published on February 28, 2013. This PDR® Drug Alert was delivered electronically to all Arkansas Medical… Read More
-
FDA Drug Alert Issued for Xeljanz
An important FDA-approved Drug Alert for XELJANZ affecting Rheumatologists, Infectious Disease, Family Medicine/General Practice, Internal Medicine and Emergency Medicine physicians was published on November 20, 2012. This PDR® Drug Alert was delivered electronically to all… Read More
-
FDA-approved Drug Alert Issued
An important FDA-approved Drug Alert for BONIVA affecting Family Medicine/General Practitioners, Internal Medicine, Endocrinology, Diabetes & Metabolism and Obstetrics & Gynecology was published on October 1, 2012. This PDR® Drug Alert was delivered electronically to… Read More